456 Studies Now Enrolling
Genentech MA29895: An exploritory multicenter, open-label, single arm study of the safety and tolerability of Pirfenidone (ESBRIET) in combination with Nintedanib (OFEV) in patients with idiopathic pulmonary fibrosis
A study for patients with idiopathic pulmonary fibrosis using study drug Pirfenidone (ESBRIET) in combination with Nintedanib (OFEV)
| Sponsor: | Genentech |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ4059 |
| Contact: | Nina Patel: 212-305-1544 / np2199@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to investigate the safety of adding nentedanib to treatment with pifenidone in patients with Idiopathic Pulmonary Fibrosis (IPF). Eligible patients must be receiving consistent treatment with pifenidone for at least 16 weeks on a stable dose. Nintedanib will be added as an additional treatment for IPF (combination treatment) for 24 weeks. This is a phase IV, open-label, singlearmed trial. Participants will have center visits weekly for the first 4 weeks, and biweekly until 24 weeks.
This study is closed
